Elligo Health Research, a healthcare-enabling research organization, is helping Jack Nathan Health patients gain access to clinical research as a care option at its Canadian Walmart clinics. Jack Nathan Health operates physician-led medical practices that accommodate clinic appointments, lab services, physiotherapy and chiropractic services, and more.
“We take our commitment to exceptional service and care seriously,” said George Barakat, CEO at Jack Nathan Health. “Partnering with Elligo gives us the opportunity to stay informed of the newest advancements, improve our cutting-edge facilities, and continue to meet our patients’ healthcare challenges.”
This partnership expands Elligo’s Research Ready site network to include healthcare experts and their patients from across. Jack Nathan Health patients who qualify for a research study will be given the opportunity to receive treatment through Elligo’s Goes Direct approach, which connects drug development companies to a diverse pool of patients.
“To date, this is our greatest achievement in our mission to connect research to patients,” said John Potthoff, PhD, CEO of Elligo.
Driving Diversity with the Integrated Research Model
October 16th 2024Ashley Moultrie, CCRP, senior director, DEI & community engagement, Javara discusses current trends and challenges with achieving greater diversity in clinical trials, how integrated research organizations are bringing care directly to patients, and more.
Vabysmo Shows Significant Vision Improvement for Diabetic Macular Edema in Underrepresented Patients
October 22nd 2024Phase IV ELEVATUM trial results show that one year of treatment with Vabysmo significantly improved vision in underrepresented racial and ethnic groups with diabetic macular edema, supporting the drug's efficacy and safety across diverse populations.
AI in Clinical Trials: A Long, But Promising Road Ahead
May 29th 2024Stephen Pyke, chief clinical data and digital officer, Parexel, discusses how AI can be used in clinical trials to streamline operational processes, the importance of collaboration and data sharing in advancing the use of technology, and more.
Clesrovimab Shows Significant Reduction in RSV Infections, Hospitalizations in Infants
October 18th 2024Merck's investigational monoclonal antibody, clesrovimab, shows significant efficacy in reducing respiratory syncytial virus-related infections and hospitalizations in infants, with a favorable safety profile.